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Background: Chlamydia is the most commonly reported bacterial sexually transmitted infection in Europe. The objective of the
Screening for Chlamydia in Europe (SCREen) project was to describe current and planned chlamydia control activities in Europe.
Methods: The authors sent a questionnaire asking about different aspects of chlamydia epidemiology and control to public
health and clinical experts in each country in 2007. The principles of sexually transmitted infection control were used to develop
a typology comprising five categories of chlamydia control activities. Each country was assigned to a category, based on
responses to the questionnaire. Results: Experts in 29 of 33 (88%) invited countries responded. Thirteen of 29 countries
(45%) had no current chlamydia control activities. Six countries in this group stated that there were plans to introduce chlamydia
screening programmes. There were five countries (17%) with case management guidelines only. Three countries (10%) also
recommended case finding amongst partners of diagnosed chlamydia cases or people with another sexually transmitted
infection. Six countries (21%) further specified groups of asymptomatic people eligible for opportunistic chlamydia testing.
Two countries (7%) reported a chlamydia screening programme. There was no consistent association between the per capita
gross domestic product of a country and the intensity of chlamydia control activities (P=0.816). Conclusion: A newly developed
classification system allowed the breadth of ongoing national chlamydia control activities to be described and categorized.
Chlamydia control strategies should ensure that clinical guidelines to optimize chlamydia diagnosis and case management have
been implemented before considering the appropriateness of screening programmes.
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Introduction
Sexually transmitted Chlamydia trachomatis is the most frequentlyreported of all notifiable infections in several industrialized count-
ries and reported diagnoses are increasing.1–3 Chlamydia prevalence
is highest in women <25 years and men <30 years: 2–6% of adults
in the general population in high-income countries are estimated to
be infected,4–8 and most are asymptomatic.8 Untreated chlamydia can
cause infertility and ectopic pregnancy in women and epididymo-
orchitis in men.9 Chlamydia is associated with adverse pregnancy
and neonatal outcomes and facilitation of HIV transmission.9
The general principles of sexually transmitted infection control
include early diagnosis and effective treatment of infected cases
and, through partner notification, sexual partners who might
have infected the case or might have been exposed to infection.10
Screening of asymptomatic individuals is frequently recommended
as an intervention11–14 since >95% of chlamydia-infected women
and men in population-based surveys are asymptomatic.8 The ways
in which case management, screening, surveillance and other
components of chlamydia control are incorporated into
communicable disease control programmes in different countries
are, however, not well understood. The objectives of this study
were to describe the range and intensity of existing and planned
chlamydia control activities in Europe.
Methods
The Screening for Chlamydia Review in Europe (SCREen) project
was conducted between November 2006 and January 2008. The
methods and results are described in detail in a technical
report.15 The project was commissioned by the European Centre
for Disease Prevention and Control (ECDC) to investigate public
health activities that contribute to the control of sexually
transmitted genital C. trachomatis in Europe and to aid develop-
ment of guidance for European Union Member States.16 We
invited all Member and candidate states of the European Union
(as of November 2006) and countries in the European Free Trade
Association (EFTA); Iceland, Liechtenstein, Norway and
Switzerland.
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We designed a structured questionnaire in English, which asked
about: the existence, audience and content of guidelines on the
management of genital chlamydia; laws and policies about sexually
transmitted infection control; diagnosis of chlamydia; surveillance
of chlamydia and its complications; the organization of and
payment for clinical services; existing or planned screening pro-
grammes; and publications about chlamydia prevalence and sexual
behaviour, if available. These data were supplemented by inclusion
in the database of economic and demographic information on each
country.
The questionnaire was sent in January 2007 by e-mail or post to
public health and clinical experts in each country, identified
through lists of representatives of the European Surveillance for
Sexually Transmitted Infections network and the International
Union against Sexually Transmitted Infections Europe group.
They were asked to involve experts with specialist knowledge if
they themselves did not know the answers. We sent multiple
reminders. Country representatives reviewed the preliminary ana-
lysis; the data used in this report include all responses, amendments
and clarifications received by 14 January 2008.
We developed a system for classifying chlamydia control acti-
vities at the country level using items from the questionnaire and
the principles of sexually transmitted infection control.10 The
resulting categories described criteria that required increasing
technical and organizational capacity for implementation
(Supplementary Web table S1). Case management for diagnosed
cases was assessed from guidelines, which we considered an
essential requirement for delivering and monitoring consistent
care. Case finding for partners of diagnosed cases was considered
a requirement for chlamydia control and documentation of this
in guidelines was required. We made two categories for activities
aimed at early chlamydia detection. Opportunistic chlamydia
testing was defined as testing offered to groups of asymptomatic
patients attending health-care settings, where the onus is on the
health professional to repeat the offer at regular intervals.17 A
chlamydia screening programme was defined as organized system-
atic screening as part of the public health system. We assessed
screening programme activities against a published checklist.18
Questionnaire data were reviewed by two pairs of project team
members. Each pair examined one half of the participating count-
ries and each member of the pair independently assigned the
relevant country to a category. No reviewer assessed data from
their own country. Discrepancies were resolved by discussion or
the decision of a third person. Where the activities of a country
spanned different categories, we assigned the lowest.
Data were entered into an Access (Microsoft Office) database.
The data were summarized descriptively. We made a limited num-
ber of statistical comparisons using Kruskal–Wallis tests for non-
normally distributed continuous data and chi-squared tests for
categorical data. We use the term ‘sexually transmitted infection
specialists’ to refer to all such specialists, including dermatovener-
eologists and genitourinary medicine specialists.
Results
Of the 33 invited countries, we received responses from more than
80 experts in a total of 29 (88%) countries. We could not collect
information from Croatia, Cyprus, Poland and Slovakia.
Clinical practice guidelines
Among 29 participating countries, experts in 17 reported 32 sets of
guidelines for the management of genital chlamydial infection
endorsed by a nationally recognized professional organization
(table 1). Three countries were in the process of publishing or
preparing guidelines and nine had no guideline. Ten countries
had a guideline intended for all practitioners. In four of these
different professional groups had developed separate guidelines
(table 1). The content of different guidelines in the same country
was sometimes inconsistent. In The Netherlands, for example, a
guideline for all practitioners is published by the Institute for
Healthcare Quality. There are separate guidelines for primary
care, sexually transmitted infection specialists, gynaecologists and
municipal health service staff. The eligible age groups and recom-
mendations about repeat testing differ. Audit 19 of adherence to
guidelines was only practised in genitourinary medicine clinics in
the UK.
Availability of chlamydia testing
Chlamydia testing was available in many settings, including all
26 participating countries with specialist clinics and gynaecology
clinics in all 29 countries (table 2). In 17 countries, gynaecology clinics
were the most likely setting for chlamydia testing. Chlamydia testing
was also available in most countries in urology, primary care and
family planning clinics. In five countries, chlamydia testing kits
could be bought in pharmacies or other over-the-counter outlets.
Settings where chlamydia testing could be carried out were not always
Table 1 Coverage of chlamydia case management guidelines in
Europe
Guideline audience (N=29) Countries
Single guideline for all practitioners
(n=6)
Estonia, Hungary, Iceland,
Lithuania, Norway, Romania
Guideline for all practitioners PLUS
separate specialist guidelinesa
(n=4)
Belgium, Czech Republic,
Sweden, The Netherlands
Sexually transmitted infection
specialists only (n=3)
Austria, France, Italy
Guideline for sexually transmitted
infection specialists PLUS separate
specialist guidelinesb (n=2)
Latvia, UK
Primary care practitioners only (n=1) Denmark
Antenatal clinics/urology only (n=1) Germany
Guideline in preparationc (n=3) Bulgaria, Finland, Greece
No guidelinec (n=9) Ireland, Liechtenstein,
Luxembourg, Malta, Portugal,
Slovenia, Spain, Switzerland,
Turkey
a: Includes any combination of dermatovenereology, primary
care, gynaecology, youth clinics, municipal health services
b: Includes gynaecology (Latvia), tests being done for chlamydia
screening programme (UK, England only)
c: As of January 2008. Adapted from Table 5, Ref. 15.
Table 2 Availability of chlamydia testing and of clinical guidelines
in specified settings
Setting Chlamydia
testing
available, n
Most
common
setting, na
Practitioners
not covered
by guidelineb,
n (%)
Gynaecology 29 17 16 (55)
Sexually transmitted
infection clinic
26 2 12 (46)
Urology 25 3 17 (68)
Primary care 23 11 13 (57)
Family planning 22 2 13 (62)
Internal medicine 11 0 7 (64)
Emergency department 10 0 6 (60)
Pharmacy 5 0 Not knownc
a: Countries could rank more than one setting as the most likely
place for testing, so total is more than the number of countries
b: Denominator is number of countries in which chlamydia testing
is available at each setting
c: Questionnaire did not ask whether guidelines covered
non-clinical settings. Reproduced from Table 8, Ref. 15.
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covered by case management guidelines. In 16/29 countries where
chlamydia testing was available in gynaecology clinics, there was
no clinical guideline, i.e. no guideline applicable to all practition-
ers. In nine of these countries, this was the most common setting
for chlamydia testing. Nearly half (12/26) of countries with
specialist sexually transmitted infection clinics did not have a
guideline for these practitioners (table 2).
Partner notification
Of 32 guidelines, recommendations about partner notification were
included in 26. In most non-specialist settings where chlamydia
testing was offered, partner notification was reported to be initiated
by the physician in the clinic. In a minority of countries respond-
ents explicitly noted that no partner notification took place. This
was most frequently reported about family planning clinics (5/22).
Laboratory diagnosis
Nucleic acid amplification tests for chlamydia diagnosis, which are
the most accurate but also the most expensive assays,20 were avail-
able to some extent in all but one country (Bulgaria) but were not
always available for routine testing. The percentage of tests
analysed using nucleic acid amplification tests was <10% in five
countries, 10–49% in four, 50–90% in five and >90% in 11. There
was statistical evidence of an association between increasing per
capita gross domestic product (GDP) and the level of nucleic acid
amplification testing (P= 0.003). Countries in which laboratories
took part in diagnostic quality assurance schemes were more likely
to also have clinical guidelines for at least one group of health
professionals (15/19) than those that did not (4/10, P= 0.036).
Surveillance for chlamydia
Most countries (25/29) reported some system for surveillance of
chlamydia infections. The most common method was a statu-
tory requirement for reporting of all laboratory diagnosed cases
(15 countries). Seven countries conducted surveillance in selected
sentinel sites or with reporting only from sexually transmitted
infection clinics. Nine countries did not publish surveillance data
about chlamydia and in three countries reporting from laborato-
ries was voluntary. The recorded rate of diagnosed chlamydia
differed markedly between countries, even within the group
where reporting of diagnosed cases was reported to be compulsory
(figure 1).
Categorization of chlamydia control activities
The category to which each country was assigned is shown in table 3.
There was no consistent association between median GDP across
categories of chlamydia control activities (P= 0.816). The group
with no organized activity included countries in Europe with the
highest (Liechtenstein and Luxembourg) and lowest (Turkey and
Bulgaria) per capita GDP.
No organized chlamydia control activity
The largest category (13/29, 45%) was of countries that were
defined as having with no current activities because they did not
have a nationally recommended guideline, or because the availabil-
ity of services was very limited (table 3). Six countries in this group
stated plans to introduce chlamydia screening programmes.
Case management for diagnosed chlamydia
There were five countries (17%) in this group (table 3). The
guidelines in Lithuania and the Czech Republic applied to all prac-
titioners. They applied only to sexually transmitted infection spe-
cialists in Austria and Italy, and gynaecologists and urologists in
Germany. Chlamydia testing in these countries was usually,
however, widely available in other clinical settings (table 1).
Case finding for partners of infected cases
Three countries (10%) were included in this category (table 3).
Although case management guidelines for other countries were
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Figure 1 Rate of diagnosed chlamydia cases per 100 000 population in Europe, 2005 or 2006. Figure includes data from all countries that
provided data about reported chlamydia cases in 2005 or 2006. Numerator is the number of diagnosed chlamydia cases reported;
denominator is the total mid-year population of the country in the year of data collection. Countries with selective reporting include
those that publish data about all cases reported from sentinel sites, including countries that report all cases diagnosed in specialist clinics.
Countries with no apparent cases either did not provide data, or did not have data available. Reproduced from Figure 4, Ref. 15
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reported to cover partner notification, we only included those that
explicitly stated that partners of diagnosed chlamydia cases or
people with another sexually transmitted infection should be
offered chlamydia testing.
Opportunistic chlamydia testing
Six countries (21%) specified groups of asymptomatic people
eligible for chlamydia testing at selected settings (table 3). The
groups offered testing differed between countries but most
commonly included sexually active adolescents and young adults
with multiple sexual partners or a recent change of partner, and
women undergoing uterine instrumentation. In Sweden, oppor-
tunistic chlamydia testing takes place across the country in a
variety of clinical settings. Diagnosis and treatment are free and
partner notification is mandatory.21
Chlamydia screening programmes
Two countries (The Netherlands and the UK, 7%) reported a
chlamydia screening programme covering a substantial part of
the population that was ongoing or was being conducted as a
pilot programme (table 3). In the UK, chlamydia screening was
introduced in England in 2003 and rolled out across that country
by the end of 2007.22 Screening tests are offered opportunistically
to sexually active women and men aged <25 years attending
selected settings, depending on the area and, in some places,
through outreach activities. When assessed against the checklist
Table 3 Level of chlamydia control activities for European countries participating in project SCREen
Country Comments
No organized chlamydia control activity (n=13)
Bulgaria Case management guideline, planned publication January 2008. Screening programme planned.
Finland Case management guideline planned for development 2008. Opportunistic programme planned.
Greece No case management guideline. Screening programme planned.
Ireland No case management guideline.
Liechtenstein No case management guideline.
Luxembourg No case management guideline. Opportunistic screening programme planned.
Malta No case management guideline.
Portugal No case management guideline.
Romania Case management guideline for all practitioners, but very limited facilities for testing in practice.
Slovenia No case management guideline. Screening programme planned.
Spain No case management guideline.
Switzerland No case management guideline.
Turkey No case management guideline. Screening programme planned.
Case management for diagnosed chlamydia cases (n=5)
Austria Case management guideline for sexually transmitted infection clinics. Chlamydia testing available in other settings but partner
notification done in primary care only.
Czech Republic Case management guideline for all practitioners deals with diagnosis but not treatment or partner notification. Partner notifi-
cation reported to be by referral to specialist clinic.
Germany Case management guideline for gynaecology (pregnant women) and urology. Chlamydia testing not done in primary care. Partner
notification reported to be done by practitioner in gynaecology (where most tests are done), urology, internal medicine, but not
in family planning clinics.
Italy Case management guideline for sexually transmitted infection clinics. Chlamydia testing for symptomatic people only. Chlamydia
testing and partner notification available in other settings.
Lithuania Case management guideline for all practitioners includes partner management, but no list of who should be offered chlamydia
testing and, in practice, said not to take place.
Case finding for partners of diagnosed chlamydia cases (n=3)
Belgium Partner management included in guideline for primary care (where most tests are done) and gynaecology. Primary care guideline
includes testing only for female partners of symptomatic men.
France Case management guideline for sexually transmitted infection clinics. Testing recommended for partners of cases with sexually
transmitted infection. Chlamydia testing available in many other settings and partner notification reported to be done by
patient referral initiated by practitioner. Screening programme planned.
Hungary Case management guideline for all practitioners, including chlamydia testing for all sexual partners of symptomatic patients with a
sexually transmitted infection. In practice, partner notification might not take place.
Opportunistic testing for selected asymptomatic individuals (n=6)
Denmark Guideline includes opportunistic chlamydia testing in primary care (where most tests are done) for asymptomatic people with
frequent sex partner change, women <26 years before intrauterine device insertion or hysterosalpingogram. Also annual postal
invitation for screening in two communities.
Estonia Guideline for all practitioners includes opportunistic testing for pregnant women and asymptomatic people with frequent sex
partner change, clients of commercial sex workers, following sexual assault.
Iceland Guideline for all practitioners includes opportunistic testing for women presenting for termination of pregnancy, egg and sperm
donors.
Latvia Opportunistic testing recommended for pregnant women. Partner management included in guideline for sexually transmitted
infection and gynaecology clinics, including chlamydia testing for partners of patients with a sexually transmitted infection.
Partner notification done by practitioner or by referral to specialist clinic.
Norway Guideline for all practitioners includes opportunistic testing for women presenting for termination of pregnancy or antenatal care,
<25 s with recent partner change, and partners of people with a sexually transmitted infection. Plans for proactive chlamydia
screening by postal invitation following randomized controlled trial in one region.
Sweden Multiple guidelines for different practitioners. Include opportunistic testing for asymptomatic people with target groups differing
between counties.
Organized chlamydia screening programme (n=2)
The Netherlands Pilot chlamydia screening programme began March 2007. Annual postal invitation for chlamydia screening to all 16–29 year olds in
three regions from September 2008.
UK (England) Opportunistic chlamydia screening offered to all sexually active <25-year-olds attending various clinical and non-clinical settings
(depending on health district). Rolled out 2003 to March 2007.
Reproduced from Table 14, Ref. 15.
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of Gray,18 most criteria were fulfilled, but the proportion of
positive cases was not accepted as a valid performance measure
of chlamydia prevalence, and incidence of complications was
planned but not implemented. The programme did not cover
Scotland, Wales or Northern Ireland. In The Netherlands, the
Chlamydia Screening Implementation project is a pilot programme
in three regions of the country, which began in March 2007.23
Chlamydia screening invitations are delivered at yearly intervals
to men and women aged 16–29 years using population registers.
Recipients request a home sampling kit through a web-based
application. In two regions, all those in the target age group are
invited; in one region eligibility is assessed by a web-based ques-
tionnaire. The main objectives and performance measures were
valid. The programme will be evaluated using a randomized
design. In both programmes there were features that were still
under development.
Nine countries reported plans to introduce chlamydia screening
programmes in the future, including six with no current chlamydia
control activities (table 3). Four programmes are planned to be
delivered using an opportunistic approach (Finland, France, Greece,
Luxembourg), compared with one (Norway) planned as a proactive,
register-based programme. In four countries, the target population
includes specific groups at high risk of chlamydia such as sex
workers (Greece, Turkey), Roma (Bulgaria) and attenders at
sexually transmitted infection clinics (France, Greece).
Monitoring the outcomes of chlamydia control
activities
Three countries (France, England in the UK and The Netherlands)
reported existing or planned performance targets. In England,
there were no indicators measuring the primary outcomes of the
screening programme (reduced reproductive tract complications
and transmission). In The Netherlands, proposed indicators
include changes in population prevalence and pelvic inflammatory
disease incidence as well as uptake of repeated screening invita-
tions. The specific indicators in France were not reported.
Informants from four countries that reported plans to introduce
chlamydia screening (Bulgaria, Germany, Greece, Norway),
reported that routine data about the complications of chlamydia
were not collected.
Discussion
This study identified wide variation across 29 European countries
in the range and intensity of activities that contribute to the
control of sexually transmitted chlamydia infections. Surveillance
data showed the differences between countries in reported rates of
diagnosed cases. Seventeen countries had at least one guideline
about the diagnosis and management of chlamydia infections.
Thirteen countries have no organized activities aimed at chlamydia
control; five have organized case management; three undertake
additional case finding activities; seven recommend opportunistic
testing and two reported an ongoing or pilot screening
programme.
A major strength of the SCREen project was the collection and
synthesis of comparable information about a wide range of sexually
transmitted infection control activities, with a high response rate.
The survey included countries in Central and Eastern Europe that
are Member States of the European Union. The involvement of
informants from different disciplines enabled collection of infor-
mation about diverse areas of policy and practice. A weakness of
this study is that it only gives a cross-sectional overview at the
national level, masking potentially important regional differences
in countries with devolved funding. Furthermore, we probably
obtained more accurate information about what is recommended
than about actual practice. Despite using structured questions,
there was inevitably some room for them to be interpreted differ-
ently by different respondents, particularly since the questionnaire
was only written in English. This might have led to misclassifica-
tion, although we tried to obtain clarification and key informants
commented on the draft report.15 Reliability of categorization was
increased by having two assessments, but could have been
improved by having a third external assessor.
The wide range of policies and practices might reflect a lack of
agreement about the most appropriate and effective chlamydia
control measures. Reviews of the evidence available show that
there are effective tools for the prevention, diagnosis, antibiotic
treatment and partner management of sexually transmitted
infections, including chlamydia.24 There is also evidence from
randomized controlled trials25–27 that the incidence of PID in
women might be reduced by about half with high uptake
(64–100%) of a single round of testing and treatment. There is
an absence, however, of empirical evidence from studies with a low
risk of bias about the relationship between the intensity of
chlamydia control and the impact on transmission.28 Screening
programmes are the most organizationally demanding of control
measures.18,29 This survey found that the performance measures
for the English screening programme did not include the primary
outcomes. An independent evaluation of the English programme
in 2009 also found that the programme had been introduced
without robust data about population prevalence or evidence for
the effectiveness of screening.30 The first priority for research is,
therefore, to establish the relationship between the intensity of
chlamydia control activities and their impact on chlamydia preva-
lence and reproductive tract morbidity. The Dutch Chlamydia
Screening Implementation project included in this study will be
the first pragmatic population-based randomized trial worldwide to
determine whether or not the benefits of proactive register-based
chlamydia screening can be achieved and sustained over multiple
rounds.23 A randomized trial that began in 2010 in Australia
will provide information about the effectiveness of opportun-
istic chlamydia screening in reducing chlamydia prevalence in
2014–15.31
A report about screening policies in European Union Member
and Applicant States included unstructured descriptions about
chlamydia screening in 2004,32 which were broadly consistent
with this study. The advantage of the present study was that we
used uniform definitions that allowed the categorization of
countries. Of note, both surveys reported that there was no
organized chlamydia screening programme in Sweden because
the widespread opportunistic screening activities are not
nationally coordinated. Chlamydia screening activities have
previously been widely described as an organized programme by
both Swedish33,34 and international researchers and public health
organizations.35
Disease control programmes for sexually transmitted infection
should provide primary prevention and comprehensive case
management.24 These are features of disease control that should
be optimized 14 before considering screening programmes.36 The
consistency and quality of case management are more likely to be
assured if clinical guidelines are in place and adherence to them is
audited. It is, therefore, notable that this study identified several
countries that reported plans to introduce screening programmes,
yet had no nationally recognized guidelines for the management of
diagnosed cases or their partners. Furthermore, while the UK was
the only country in which clinical audit was a routine practice, this
took place only in genitourinary medicine clinics. The study also
showed that partner notification was not always integrated into
chlamydia case management, or was not always done even when
recommended. Partner notification efforts seem likely to be sub-
optimal if practitioners are working in settings that are not covered
by any guidelines.
The SCREen project provides baseline information about chla-
mydia control activities in place in 2007 in European countries and
has informed a guidance document for European Union Member
States.16 The results of this survey and the guidance document can
be used to audit progress in the development of chlamydia control
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strategies, with assessment against measurable standards.19 An
update of the survey would provide valuable information to
monitor changes in the intensity of chlamydia control activities
at country level, introduction of planned activities and adoption
of recommendations. Of interest, economic resources did not seem
to be associated with the priority assigned to chlamydia control in
participating countries. The results of this survey indicate that the
majority of chlamydia infections in the populations of European
countries continue to go undetected with the risk of subsequent
complications and onward transmission. Chlamydia control
strategies should ensure that there are primary preventive
activities and clinical guidelines to optimize chlamydia diagnosis
and case management before considering the appropriateness of
screening programmes.
Supplementary data
Supplementary data are available at Eurpub online.
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Key points
 Chlamydia trachomatis is the most commonly notified
sexually transmitted infection in most developed countries.
 The most effective and cost-effective strategies for
controlling chlamydia transmission are not known.
 Activities that contribute to chlamydia control vary widely
in Europe, with many countries having no organized
activities.
 Chlamydia control strategies should ensure that clinical
guidelines to optimize chlamydia diagnosis and case
management have been implemented before considering
the appropriateness of screening programmes.
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